Out-of-pocket costs of diabetes medications other than insulin can be quite high for individuals with employer-sponsored health insurance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.37765/ajmc.2024.89510 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Test Utilization and Cost among Families of Children Evaluated for Genetic Conditions: An Analysis of USA Commercial Claims Data.
Appl Health Econ Health Policy
January 2025
Department of Population Medicine, Harvard Pilgrim Health Care Institute, 401 Park Drive, Suite 401, Boston, MA, 02215, USA.
Introduction: Healthcare payers in the USA increasingly cover genetic testing, including exome sequencing (ES), for pediatric indications. Analysis of claims data enables understanding of utilization and costs in real-world settings. The objective of this study was to describe genetic test utilization, diagnostic outcomes, and costs for children who received ES as well as for those who received less comprehensive forms of genetic testing, along with their families.
View Article and Find Full Text PDFFinancial challenges of being on long-term, high-cost medications.
Neurooncol Pract
February 2025
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
The isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, may offer a promising new treatment option for patients with IDH-mutant gliomas. However, the indefinite nature of this targeted therapy raises significant financial concerns. High costs of targeted cancer therapies, often exceeding $150 000 annually, contribute to financial toxicity, characterized by medical debt, income loss, and psychological stress, and place stress on health systems.
View Article and Find Full Text PDFWillingness to pay for exercise oncology services: a mixed methods study.
Support Care Cancer
January 2025
Department of Health Services Research, Peter MacCallum Cancer Centre, Victoria, Australia.
Purpose: To evaluate cancer patients' willingness to pay for exercise services and oncology health professionals' perception of patients' willingness to pay.
Methods: A mixed-methods design was used. Online questionnaires and semi-structured interviews were administered to people with any type of cancer and oncology health professionals delivering clinical care.
Validity of the Actigraph-GT9X accelerometer for measuring steps and energy expenditures in heart failure patients.
PLoS One
January 2025
Department of Kinesiology and Health Science, Virginia Commonwealth University, Richmond, VA, United States of America.
Introduction: The ActiGraph (AG) accelerometer is widely used to assess physical activity (PA) in heart failure (HF) patients. However, the validity of the AG in this population remains unexplored.
Objective: Therefore, this study examined the criterion validity of the AG-GT9X for measuring step counts (SC) and energy expenditure (EE) among HF patients.
The short-term impact of copayment reductions for government subsidized medicines in Australia.
Expert Rev Pharmacoecon Outcomes Res
January 2025
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney.
Background: This study aimed to examine the short-term, population-level effects of the 2023 Australian Pharmaceutical Benefits Scheme (PBS) copayment reduction on prescription volume, patients' out-of-pocket (OOP) expenditure, and government contributions.
Research Design And Methods: We conducted a quasi-experimental study using national data from January 2021 to April 2024. For system-level analysis, we examined all drugs used by general patients, focusing on 252 drugs that were 'above copayment' during 2022-2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!